STERIS plc (Ireland) Ordinary Shares (STE) Company Bio
Steris Corporation develops, manufactures, and markets infection prevention, contamination control, microbial reduction, and procedural support products and services for healthcare, pharmaceutical, scientific, research, industrial, and governmental customers worldwide. The Company operates through three business segments: Healthcare, Life Sciences and STERIS Isomedix Services. The company was founded in 1985 and is based in Mentor, Ohio.
STE Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for STE, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that STERIS plc ranked in the 42th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of STERIS plc, consider:
The company's debt burden, as measured by earnings divided by interest payments, is 14.92; that's higher than 75.77% of US stocks in the Healthcare sector that have positive free cash flow.
The business' balance sheet suggests that 7% of the company's capital is sourced from debt; this is greater than merely 20.6% of the free cash flow producing stocks we're observing.
STE's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 40.11% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of STERIS plc? See QDEL, AMGN, NVS, ADUS, and MEDP.
DUBLIN, IRELAND, Jan. 19, 2021 (GLOBE NEWSWIRE) — STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2021 third quarter financial results at 10:00 a.m. ET on Wednesday, February 3, 2021. The conference call can be heard live at www.steris-ir.com or via phone… Read More »STERIS to Host a Conference Call for Fiscal 2021 Third Quarter Financial Results on February 3, 2021
DUBLIN, IRELAND, Jan. 19, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2021 third quarter financial results at 10:00 a.m. ET on Wednesday, February 3, 2021. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing third quarter financial results will be issued after the U.S. market closes on Tuesday, February 2, 2021. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on February 3, 2021, either at www.steris-ir.com or via phone. To access the replay...
WILMINGTON, Del., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Cantel Medical Corp. (“Cantel”) (NYSE: CMD) regarding possible breaches of fiduciary duties and other violations of law related to Cantel’s agreement to be acquired by STERIS plc (“STERIS”) (NYSE: STE). Under the terms of the agreement, Cantel’s shareholders will receive approximately $16.93 in cash and 0.33787 of a share of STERIS per share. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-cantel-medical-corp.You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or [email protected] Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on b...
Steris has agreed to snap up peer Cantel Medical Corp in a cash and stock deal valued at $3.6 billion, in what marks another consolidation move in the healthcare sector. Under the terms of the agreement, Steris (STE) has offered to pay $84.66 per Cantel common share, based on Steris’ closing share price of $200.46 on Jan. 11. Cantel stockholders will get about $16.93 in cash and 0.33787 of a Steris ordinary share for each Cantel share they own. Cantel shares closed at $83.87 on Jan. 12. The deal translates into a total enterprise value of about $4.6 billion, including Cantel’s net debt and convertible notes.